Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 10418922)

1.

Vaccination with Rev and Tat against AIDS.

Osterhaus AD, van Baalen CA, Gruters RA, Schutten M, Siebelink CH, Hulskotte EG, Tijhaar EJ, Randall RE, van Amerongen G, Fleuchaus A, Erfle V, Sutter G.

Vaccine. 1999 Jun 4;17(20-21):2713-4. No abstract available.

PMID:
10418922
2.

A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.

Xin KQ, Urabe M, Yang J, Nomiyama K, Mizukami H, Hamajima K, Nomiyama H, Saito T, Imai M, Monahan J, Okuda K, Ozawa K, Okuda K.

Hum Gene Ther. 2001 Jun 10;12(9):1047-61.

PMID:
11399227
3.

Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.

Verrier B, Le Grand R, Ataman-Onal Y, Terrat C, Guillon C, Durand PY, Hurtrel B, Aubertin AM, Sutter G, Erfle V, Girard M.

DNA Cell Biol. 2002 Sep;21(9):653-8.

PMID:
12396607
4.

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, Miedema F, Gruters RA, Osterhaus AD.

J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8.

5.

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.

Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP, Goulder PJ, Walker BD; HIV Controller Study Collaboration.

Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1781-6.

6.

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes.

Gruters RA, van Baalen CA, Osterhaus AD.

Vaccine. 2002 May 6;20(15):2011-5. Review.

PMID:
11983265
7.

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.

Calarota SA, Kjerrström A, Islam KB, Wahren B.

Hum Gene Ther. 2001 Sep 1;12(13):1623-37.

PMID:
11535166
8.

Enhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras, Tat and Rev.

Chenciner N, Randrianarison-Jewtoukoff V, Delpeyroux F, Hanania N, Pedroza Martins L, Stratford Perricaudet L, Perricaudet M, Wain-Hobson S.

AIDS Res Hum Retroviruses. 1997 Jun 10;13(9):801-6.

PMID:
9171225
9.

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, Goletti D, Borsetti A, Pace M, Fanales-Belasio E, Ridolfi B, Negri DR, Sernicola L, Belli R, Corrias F, Macchia I, Leone P, Michelini Z, ten Haaft P, Buttò S, Verani P, Ensoli B.

Vaccine. 2001 Apr 6;19(20-22):2862-77.

PMID:
11282197
10.

HIV regulatory and accessory proteins: new targets for vaccine development.

Robert-Guroff M.

DNA Cell Biol. 2002 Sep;21(9):597-8. No abstract available.

PMID:
12396601
11.

Comparison of the efficacy of early versus late viral proteins in vaccination against SIV.

Stittelaar KJ, Gruters RA, Schutten M, van Baalen CA, van Amerongen G, Cranage M, Liljeström P, Sutter G, Osterhaus AD.

Vaccine. 2002 Jul 26;20(23-24):2921-7.

PMID:
12126903
12.

SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.

Cafaro A, Caputo A, Maggiorella MT, Baroncelli S, Fracasso C, Pace M, Borsetti A, Sernicola L, Negri DR, Ten Haaft P, Betti M, Michelini Z, Macchia I, Fanales-Belasio E, Belli R, Corrias F, Buttò S, Verani P, Titti F, Ensoli B.

J Med Primatol. 2000 Aug;29(3-4):193-208.

PMID:
11085582
13.

Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.

Ensoli B, Cafaro A.

J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):22-6.

PMID:
10763887
14.

AIDS. Escape from the immune system.

Walker BD, Goulder PJ.

Nature. 2000 Sep 21;407(6802):313-4. No abstract available.

PMID:
11014174
16.

Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability.

Ridolfi B, Genovese D, Argentini C, Maggiorella MT, Sernicola L, Buttò S, Titti F, Borsetti A, Ensoli B.

Virus Genes. 2008 Feb;36(1):105-15. Epub 2007 Nov 30.

PMID:
18049888
17.

Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.

Blazevic V, Männik A, Malm M, Sikut R, Valtavaara M, Toots U, Ustav M, Krohn K.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):667-77.

PMID:
16831091
18.

Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection.

Guillon C, Stankovic K, Ataman-Onal Y, Biron F, Verrier B.

AIDS Res Hum Retroviruses. 2006 Dec;22(12):1283-92.

PMID:
17209772
19.

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, Cara A, Negri DR, Buttò S, Fiorelli V, Tripiciano A, Scoglio A, Caputo A, Borsetti A, Ridolfi B, Bona R, ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Ciccozzi M, Heeney J, Titti F, Cafaro A, Ensoli B.

Vaccine. 2004 Sep 3;22(25-26):3258-69.

PMID:
15308348
20.

Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.

Ensoli B, Cafaro A, Caputo A, Fiorelli V, Ensoli F, Gavioli R, Ferrantelli F, Cara A, Titti F, Magnani M.

Microbes Infect. 2005 Nov;7(14):1392-9. Epub 2005 Sep 15.

PMID:
16243561
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk